Humana reported Q3 earnings that reflect both the pressures facing the US Medicare Advantage market and the insurer's continued progress in diversification through its CenterWell and Medicaid businesses.
The company posted EPS of $1.62 on a GAAP basis and $3.24 on an adjusted basis, in line with expectations but down from a year earlier.
From the nine months of 2025, Humana reported GAAP EPS of $16.43 and adjusted EPS of $21.10, compared with $15.72 and $18.35, respectively, during the same period in 2024.
Humana’s insurance segment benefit ratio stood at 91.1%, matching guidance and reflecting consistent underwriting performance despite elevated utilization levels. The company reaffirmed its full-year guidance for the segment at 90.1% to 90.5%.
Humana revised its 2025 GAAP EPS guidance to approximately $12.26, down from $13.77, citing the impact of one-off items and continued investment in its healthcare delivery platform. Adjusted EPS guidance was maintained at around $17.00, underscoring confidence in the company’s underlying operations.
“Our strategy of putting the consumer at the heart of everything we do is working, with solid year-to-date performance and strong momentum heading into the Annual Election Period,” said Humana president and CEO Jim Rechtin. “We feel positive about the direction we’re headed and the value we are creating for our members, patients, and investors.”
While the insurer still expects a decline in individual Medicare Advantage membership, the revised outlook - a drop of about 425,000 members - is an improvement from earlier projections of up to 500,000. The shift reflects better retention and stronger-than-anticipated sales, as Humana adjusts to the tighter reimbursement environment that has challenged profitability across the Medicare Advantage market this year.
On the other hand, Humana continues to expand beyond its core insurance business. Its CenterWell Primary Care operations grew by nearly 15%, adding 56,600 patients since the end of 2024. The CenterWell Pharmacy arm also reported strong performance, with specialty drug volumes and direct-to-consumer demand exceeding expectations.
The company is preparing for a major expansion in early 2026 with the launch of integrated dual-eligible programs in Michigan, Illinois, and South Carolina, which is part of a broader push to grow its Medicaid and value-based care portfolio.
Humana’s latest results mirror challenges seen across the US managed care sector. Major peers such as UnitedHealth Group and Elevance Health have also reported stronger underlying growth in diversified health services but face margin pressure from higher medical utilization in senior populations and increased regulatory scrutiny.
While UnitedHealth has leaned on its Optum health services arm for profit stability, Humana’s strategy has focused more tightly on its CenterWell and Medicaid operations to offset volatility in Medicare Advantage.
